A5033444900- Platelet Disorders and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hemophilia Treatment and Research
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Venous Thromboembolism Diagnosis and Management
- Chronic Lymphocytic Leukemia Research
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Multiple Myeloma Research and Treatments
- Blood groups and transfusion
- Blood properties and coagulation
- Hematological disorders and diagnostics
- Erythrocyte Function and Pathophysiology
- Blood Coagulation and Thrombosis Mechanisms
- Immunodeficiency and Autoimmune Disorders
- Hematopoietic Stem Cell Transplantation
- Monoclonal and Polyclonal Antibodies Research
- Erythropoietin and Anemia Treatment
- Autoimmune Bullous Skin Diseases
- Chemotherapy-induced cardiotoxicity and mitigation
- Drug Transport and Resistance Mechanisms
- Blood disorders and treatments
- Nutrition and Health Studies
- Bone and Joint Diseases
- Kruppel-like factors research
Wroclaw Medical University
2015-2024
University of Wrocław
2017-2023
Szpital Kliniczny Nr 1 we Wrocławiu
2016-2020
Hudson Institute
2017
John Wiley & Sons (United States)
2017
Niepubliczna Wyższa Szkoła Medyczna
1991-2007
University of Wales
1989-1990
Abstract Introduction Emicizumab promotes effective haemostasis in people with haemophilia A (PwHA). It is indicated for routine prophylaxis of bleeding episodes PwHA or without factor (F)VIII inhibitors. Aim To investigate the effect emicizumab dose up‐titration suboptimal control. Methods Data from seven completed ongoing phase III studies were pooled. Pharmacokinetics, pharmacodynamics and events evaluated before after up‐titration. Adverse (AEs) compared between Results Of 675 evaluable...
Multiple myeloma (MM) is associated with increased risk of venous and arterial thromboembolism. Formation denser poorly lysable fibrin clots observed in patients We investigated clot properties their determinants MM patients.Ex vivo plasma permeability, turbidity susceptibility to lysis were evaluated 106 at the time diagnosis vs. 100 age- sex-matched controls. had lower permeability (Ks ), compaction, indicating clots, impaired polymerization longer lag phase final (D-Dmax combined...
Induction therapy in patients with multiple myeloma increases the risk of thromboembolism. We have recently shown that tend to form denser fibrin clots displaying poor lysability. investigated effect induction on clot properties patients. Ex-vivo plasma permeability, turbidity, susceptibility lysis, thrombin generation, factor VIII and fibrinolytic proteins were compared 48 prior following 3 months therapy, mainly cyclophosphamide-thalidomide-dexamethasone regimen. Patients...
We present data collected in HemoRec, an Internet-based platform implemented 2006 15 haemophilia treatment centres Poland and compare them with the national registry of inherited bleeding disorders established since 1991 at Institute Haematology Blood Transfusion Warsaw. also analyse current status as well future perspectives. Data on 1102 patients registered HemoRec were analysed compared 4294 (status 17.08.2009). The number severe haemophilia, mild/moderate von Willebrand is 530, 328 54...
Endothelial progenitor cells (EPCs) play a key role in angiogenesis and vascular repair, although their exact functions are still disputable. The impact of EPC on left ventricular ejection fraction (LVEF) during acute myocardial infarction (MI) patients treated with primary percutaneous coronary intervention (PCI) is also under investigation. aim this study was to assess the different populations LVEF 6 months after MI PCI. included 34 documented anterior wall MI. control group consisted 19...
Since the introduction of clotting factor concentrates, life expectancy patients with hemophilia has increased from 40 years in 1960s to 60 or even 70 today. In Poland, almost all elderly have arthropathy, majority are infected hepatitis C virus (HCV), and some B human immunodeficiency virus. Liver cirrhosis associated HCV infection develops within 15 20 20% 30% these patients. Coexistent diseases related aging affecting heart, kidneys, other organs constitute another challenge. To prevent...
Abstract Objectives To present the Central European Myeloproliferative Neoplasm Organisation (CEMPO) treatment recommendations for polycythaemia vera (PV). Methods During meetings held from 2015 through 2017, CEMPO discussed PV and its recent data. Results is associated with increased risks of thrombosis/thrombo‐haemorrhagic complications, fibrotic progression leukaemic transformation. Presence Janus kinase (JAK)‐2 gene mutations a diagnostic marker standard criterion. World Health...
Abstract Background It is well established that expression of multi‐drug resistance ( MDR ) proteins 1, BCRP , 3, MRP and LRP in leukemic blasts correlates with acute myeloid leukemia AML patients’ clinical response. Assuming stem cells LSC are resistant to chemotherapy responsible for relapse, it might be clinically relevant evaluate the level relate outcome. Methods Bone marrow samples from 26 patients de novo were labeled antibodies distinguish CD 34+ 38− 123+ population against or...
In this document, Working Group for Haemostasis of the Polish Society Haematology and Blood Transfusion updates principles diagnosis treatment haemophilia A B, published first time in 2008. a companion paper (part II), management B complicated by factor VIII IX inhibitors will be covered.
Background. Acute intermittent porphyria (AIP) is an metabolic disorder characterized by a partial deficiency of the porphobilinogen deaminase, enzyme heme biosynthesis. The defect in AIP involves approximately half-normal activity deaminase (PBGD, EC 4.3.1.8), catalyzing condensation four molecules to hydroxymethylbilane. Due tissue-specific alternative transcript splicing, PBGD gene mutations within range exons 3–15 may lead classical involving erythrocytes and all other tissues. Mutations...
In this article, the Working Group for Haemostasis of Polish Society Haematology and Blood Transfusion updates principles diagnosis treatment haemophilia A B complicated by factor VIII or IX inhibitors, which were published first time in 2008. part Guidelines 2016, management without inhibitors was dealt with.
We present the case where immune thrombocytopenia (ITP) and essential thrombocythemia (ET) sequentially appeared in space of twenty-one years follow-up. Impaired platelet production is both diseases, but clinical presentation treatment are different. On basis this history a possible role autoimmunity as predisposing factor to myeloproliferation has been discussed.
Advances in hemophilia management the 20th century enabled effective and early treatment of joint other bleeds typical this disease, also a home setting. Prophylaxis became available as optimal approach to prevent hemophilic arthropathy improve patients' quality life. To increase safety, lyophilized plasma-derived factor VIII IX concentrates were subjected numerous procedures designed decrease risk transmission known unknown pathogens. During following years, recombinant preparations...
Guidelines for the prevention and treatment of venous thromboembolism (VTE) are aimed to improve patients’ safety quality life by appropriate prophylaxis deep thrombosis (DVT) pulmonary embolism (PE). These guidelines relate adult cancer patients treated non-surgically. Recommendations included in those do not paediatric patients. The presented here directed physicians other healthcare professionals taking care mentioned patients: clinical oncologists, haematologists, radiotherapists,...
In this document, the Group for Haemostasis of Polish Society Haematology and Transfusion Medicine presents guidelines use emicizumab. Emicizumab (Hemlibra®, F. Hoffmann — La Roche, Basel, Switzerland) has been licensed in European Union 2018. Poland, medicinal product available patients with congenital hemophilia A inhibitors against factor VIII since March 2020. This paper is a supplement to 2017 management haemophilia B or IX.